Diagonal Bio

The company is currently conducting a rights issue where the capital will be used to commercialize LAMPlify® in the horse, pig and fish segments. The goal for 2025 is to deliver 40 platforms.

She discusses the experiences from EQL Pharma and Respiratorius, as well as the company's CE-marked product LAMPlify® and plans for Panviral. The episode also discusses challenges and opportunities in the biotech and medtech sectors, Karin's view on the current stock market and financing climate for smaller companies, and strategies for securing capital.

During the visit, CEO Tomas Hammar and veterinarian Lisa Lidbeck talk about the importance of rapid diagnostics for competition horses. Karin Wehlin, CEO of Diagonal Bio, highlights the increasing demand for faster diagnostics in equestrian sports.

The engagement from investors was strong, resulting in relevant questions and fruitful discussions.

Impala Nordic is positive about the agreement, which is not only expected to generate revenue but also strengthen LAMPlify®'s market position.

She highlights challenges, emphasizing Bolgate's attractive business model and market position.

The company has also appointed Karin Wehlin as acting CEO after the board and former CEO, Jack Egelund Madsen, jointly decided that Jack should resign.

They've recently opted for a directed share issue and loan to strengthen the impact and focusing on the commercialization of LAMPlify™, recently CE-marked. Diagonal Bio aims to generate revenue and continue its innovative journey.

Then launch and commercialize its LAMPlify system for biomarker identification in 2023.

Jack also answers questions about Diagonal's two technologies - LAMPlify™ and PANVIRAL™.